[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352200-105":59,"doc-detail-352200-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cancer-associated-myositis-a-single-centre-20-year-experience","Cancer-associated myositis - a single-centre 20-year experience","","Cancer-associated myositis (CAM) refers to malignancy identified around the onset of idiopathic inflammatory myopathy (IIM), yet population-specific evidence remains limited. This retrospective study analyzes 113 IIM patients treated between 2001 and 2024 at a tertiary rheumatology center in Central Greece. CAM affected 25 patients (22.1%), linked to older age and dermatomyositis subtype.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-associated-myositis-a-single-centre-20-year-experience/352200/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-associated-myositis-a-single-centre-20-year-experience/352200.png","ImageObject",300,407,{"name":92,"@type":93},"MrHarris58","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How is cancer-associated myositis (CAM) defined in this study?","Question",{"text":112,"@type":113},"CAM is defined as myositis complicated by the onset or recurrence of cancer within 3 years before or after the diagnosis of myositis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What proportion of IIM patients had CAM, and which cancers were most common?",{"text":117,"@type":113},"CAM was identified in 25 patients (22.1%). Breast, ovarian, and lung cancers were the most common malignancies detected.",{"name":119,"@type":110,"acceptedAnswer":120},"Which autoantibodies and clinical features were associated with higher or lower CAM risk?",{"text":121,"@type":113},"Anti-TIF1γ conferred significantly higher risk, while anti-Jo1 lowered risk. Gottron’s papules and Holster sign were associated with CAM, whereas Raynaud’s phenomenon and interstitial lung disease appeared protective.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352200,1790232749,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Clinical Rheumatology (2026) 45:6213–6222  \n[https://doi.org/10.1007/s10067-026-08332-3](https://doi.org/10.1007/s10067-026-08332-3)  \n\n| \u003Cbr>ORIGINAL ARTICLE\u003Cbr>Cancer‑associated myositis: a single‑centre 20‑year experience | |\n| --- | --- |\n| Vasiliki Syrmou1 · Theodora Simopoulou1 · Eleni Patrikiou1 · Christos Liaskos1 · Ioannis Alexiou1 · Lazaros I. Sakkas1 · Christina G. Katsiari1 · Dimitrios P. Bogdanos1\u003Cbr>Received: 26 March 2026 / Revised: 26 March 2026 / Accepted: 23 July 2026 / Published online: 11 August 2026 © The Author(s) 2026\u003Cbr>Abstract\u003Cbr>Background Malignancy identified around the onset of idiopathic inflammatory myopathy (IIM) is referred to as cancerassociated myositis (CAM), but population-specific data remain relatively limited.\u003Cbr>Aim To describe the prevalence, clinical features, and risk factors for CAM over a 20-year period in a single tertiary centre in Greece.\u003Cbr>Methods A retrospective analysis was conducted on 113 IIM cases treated between 2001 and 2024 in our department, which is a referral centre for rheumatic disease in Central Greece. Medical records were evaluated for demographics, clinical characteristics, autoantibody profile, and comorbidities. CAM was defined as cases of myositis complicated by the onset or recurrence of cancer within 3 years before or after the diagnosis of myositis.\u003Cbr>Results CAM was identified in 25 (22.1%) patients. Older age and dermatomyositis subtype were associated with CAM. AntiTIF1γ autoantibody confers significantly higher risk (OR 6.9, p\u003C 0.001), while anti-Jo1 lowers risk (OR 0.13, p = 0.022) . Gottron’s papules and Holster sign were significantly associated with CAM. Raynaud’s phenomenon, interstitial lung disease and thenon-interstitial pneumonia pattern appeared protective. Hypothyroidism was less common, while myocardial infarction was more frequent in CAM. Breast, ovarian, and lung cancers were the most common malignancies identified. In most cases, malignancy was asymptomatic (85%) and was determined upon screening. Survival was significantly lower in CAMp\u003C0.001 with the survival rate dropping down to 45% at 31 months vs 95.9% in non-CAM. Median survival was 21 months in CAM cases (1–79 months) . Conclusion CAM accounts for a substantial proportion of IIM cases. Anti-TIF1γ positivity, older age, absence of Raynaud’s phenomenon, and absence of ILD may serve as clinical flags in our cohort. Comprehensive cancer screening, including GI endoscopy, remains vital in the initial assessment and follow-up, primarily upon relapses and lack of remission. |  |\n| Key Points\u003Cbr>• Population-based studies on cancer-associated myopathy have established a clear, strong link between idiopathic inflammatory myopathies (IIM) and malignancy, often termed cancer-associated myositis (CAM) .\u003Cbr>• This study examines CAM prevalence, features, and risk factors over 20 years at a Greek tertiary center.\u003Cbr>• CAM was present in 22% of IIM patients, mostly asymptomatic (85%), identified through screening; breast, ovarian, and lung cancers were the common malignancies.\u003Cbr>• Akin to previous studies, anti-TIF1γ autoantibody confers a significantly higher risk, while anti-Jo1 lowers risk. |  |\n\nKeywords Dysphagia · Malignancy · Myositis · Paraneoplastic phenomenon · Rash  \n* Dimitrios P. Bogdanos [bogdanos@med.uth.gr](bogdanos@med.uth.gr)[ ](bogdanos@med.uth.gr)Vasiliki Syrmou[syrmouvicky@yahoo.gr](syrmouvicky@yahoo.gr)[ ](syrmouvicky@yahoo.gr)Theodora Simopoulou[thsimopoul@med.uth.gr](thsimopoul@med.uth.gr)[ ](thsimopoul@med.uth.gr)Eleni Patrikiou[eleni_patrikiou@yahoo.gr](eleni_patrikiou@yahoo.gr)[ ](eleni_patrikiou@yahoo.gr)Christos Liaskos [liaskosch@uth.gr](liaskosch@uth.gr)  \n1  \nIoannis Alexiou [ioalexiou@uth.gr](ioalexiou@uth.gr)  \nLazaros I. Sakkas[lsakkas@med.uth.gr](lsakkas@med.uth.gr)  \nChristina G. Katsiari[cgk2005@gmail.com](cgk2005@gmail.com)  \nDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Uni","cbCaipgXLnh412ct","https://ap.wps.com/l/cbCaipgXLnh412ct","pdf",1400667,"English","# Abstract\n## Background\n## Aim\n## Methods\n## Results\n## Conclusion\n# Key Points\n# Keywords\n# Abbreviations\n# Introduction","[{\"question\":\"How is cancer-associated myositis (CAM) defined in this study?\",\"answer\":\"CAM is defined as myositis complicated by the onset or recurrence of cancer within 3 years before or after the diagnosis of myositis.\"},{\"question\":\"What proportion of IIM patients had CAM, and which cancers were most common?\",\"answer\":\"CAM was identified in 25 patients (22.1%). Breast, ovarian, and lung cancers were the most common malignancies detected.\"},{\"question\":\"Which autoantibodies and clinical features were associated with higher or lower CAM risk?\",\"answer\":\"Anti-TIF1γ conferred significantly higher risk, while anti-Jo1 lowered risk. Gottron’s papules and Holster sign were associated with CAM, whereas Raynaud’s phenomenon and interstitial lung disease appeared protective.\"}]","Cancer-associated myositis - a single-centre 20-year experience | PDF",1790098277,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd7a971f6eebe9f40c4a66b36afc9cc4.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6378dcc46a0cf7889d0de4d898b61e0f.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9886fcb98ddf134f662f74a5db8bbab1.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4770178143a4b85c5672b25f2f8fab17.webp",980,1301]